Close Menu
September 25, 2019
Sponsored by
HalioDx

Biomarker Evaluation for CAR T-Cell Therapy: Impact on Drug Development

Genome Webinar

Vice President of Translational Medicine
Kite, a Gilead Company

CAR T-cell therapy is an innovative form of immunotherapy that is finding increasing use for the management of blood cancers. While this approach has demonstrated impressive results for some patients, there are still challenges such as toxicity and difficulty in predicting which patients will respond.

The immune microenvironment is one of the factors that influences clinical outcomes, so identifying immune biomarkers is critical to maximizing the benefits of CAR T-cell therapy.

During this webinar, Adrian Bot, Vice President of Translational Medicine at Kite, a Gilead Company, explains how biomarker evaluation for CAR T-cell therapy can elucidate the mechanism of action and impact drug development.

This webinar also includes a brief overview of HalioDx's Immunogram platform and how it can provide meaningful and actionable data through biomarker testing.

Viewers of this webinar will learn:

  • How CAR T-cell therapy fights cancer cells and the associated mechanism of action.
  • Why evaluating immune biomarkers in CAR T-cells is crucial.
  • How biomarker evaluation can impact immunotherapy drug development.
Sponsored by
Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.